Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
There is an urgent need to understand the pathogenesis of coronavirus disease 2019 (COVID-19). In particular, thrombotic complications in patients with COVID-19 are common and contribute to organ failure and mortality. Patients with severe COVID-19 present with hemostatic abnormalities that mimic disseminated intravascular coagulopathy associated with sepsis, with the major difference being increased risk of thrombosis rather than bleeding. However, whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection alters platelet function to contribute to the pathophysiology of COVID-19 remains unknown. In this study, we report altered platelet gene expression and functional responses in patients infected with SARS-CoV-2. RNA sequencing demonstrated distinct changes in the gene-expression profile of circulating platelets of COVID-19 patients. Pathway analysis revealed differential gene-expression changes in pathways associated with protein ubiquitination, antigen presentation, and mitochondrial dysfunction. The receptor for SARS-CoV-2 binding, angiotensin-converting enzyme 2 (ACE2), was not detected by messenger RNA (mRNA) or protein in platelets. Surprisingly, mRNA from the SARS-CoV-2 N1 gene was detected in platelets from 2 of 25 COVID-19 patients, suggesting that platelets may take-up SARS-COV-2 mRNA independent of ACE2. Resting platelets from COVID-19 patients had increased P-selectin expression basally and upon activation. Circulating platelet-neutrophil, -monocyte, and -T-cell aggregates were all significantly elevated in COVID-19 patients compared with healthy donors. Furthermore, platelets from COVID-19 patients aggregated faster and showed increased spreading on both fibrinogen and collagen. The increase in platelet activation and aggregation could partially be attributed to increased MAPK pathway activation and thromboxane generation. These findings demonstrate that SARS-CoV-2 infection is associated with platelet hyperreactivity, which may contribute to COVID-19 pathophysiology. (Blood. 2020;136(11):1317-1329)
response, termed immunothrombosis. Immunothrombosis may drive adverse immunological and hemostatic processes, thereby contributing to adverse clinical outcomes such as vascular thrombosis, organ failure, and death.\textsuperscript{20} However, whether platelets contribute to the pathophysiology of SARS-CoV-2 infection, including thrombosis, is unknown.

In this prospective clinical study, we examined platelet gene expression and functional responses in acutely ill patients with COVID-19, compared with matched healthy donors. RNA-sequencing (RNA-seq) analysis from platelets isolated from SARS-CoV-2–infected patients revealed significant changes in platelet gene expression, including changes in immune pathways. Although platelet ultrastructure was intact, platelets were hyperreactive during SARS-CoV-2 infection, as evidenced by increased surface P-selectin expression basally and upon stimulation, and greater formation of circulating platelet-leukocyte aggregates (PLAs). Platelets from COVID-19 patients also exhibited increased aggregation, adhesion, and spreading. These hyperreactive responses were driven partly through increased generation and release of thromboxane A2. Taken together, our data provide new evidence that platelet gene expression is altered and functional responses are significantly increased during SARS-CoV-2 infection. We postulate that these changes may contribute to thrombotic events in COVID-19 patients.

**Methods**

For full details on methods, please see supplemental Methods (available on the Blood Web site).

**Study design**

Patients acutely ill with SARS-CoV-2 infection (n = 41) were recruited from the University of Utah Health Sciences Center in Salt Lake City. SARS-CoV-2 infection was confirmed by reverse transcription polymerase chain reaction (PCR; RT-PCR), in accordance with current standards. We collected acid citrate dextrose (ACD)-anticoagulated whole blood from patients hospitalized with COVID-19 from 17 March 17 to 5 June 2020. All COVID-19 patients were recruited under study protocols approved by the institutional review board (IRB) of the University of Utah (IRB# 00102638, 00093575). All patients enrolled in our study were hospitalized and were enrolled within 72 hours of hospital or intensive care unit (ICU) admission. Healthy, age-, and sex-matched donors were enrolled under a separate IRB protocol (IRB# 0051506). Each study participant or their legal authorized representative gave written informed consent for study enrollment in accordance with the Declaration of Helsinki. Enrollment criteria included age \( > 18\) years, respiratory symptoms (cough, shortness of breath) or fever, hospital admission, positive SARS-CoV-2 testing, and informed consent. We summarize demographic and illness severity data or Sequential Organ Failure Assessment (SOFA) scores in Table 1. All COVID-19 patients were hospitalized and were further stratified into non-ICU and critically ill ICU patients.

**Cell isolation, differentiation, and nomenclature**

Leukocyte-depleted platelets were isolated as previously described from whole blood drawn from SARS-CoV-2–infected patients and healthy donors.\textsuperscript{12,21-24}

**RNA preparation and sequencing**

RNA-seq and analysis were performed on total RNA extracted from platelets isolated from SARS-CoV-2–infected patients and age- and sex-matched healthy donors, as before.\textsuperscript{12,21,24} RNA-seq files were deposited in NCBI short-read archives under PRJNA634489.

**Real-time PCR**

For messenger RNA (mRNA) real-time PCR, isolated RNA was reverse transcribed using Oligo dT and random hexamers as previously described.\textsuperscript{12,23,24}

**Flow cytometry for platelet activation and PLAs**

Whole blood flow cytometry for platelet activation and PLAs was done as previously described.\textsuperscript{21,25,26}

**Aggregation**

Aggregation was measured using a lumi-aggregometer (Chrono-Log, Havertown, PA) at 37°C under stirred conditions as previously described.\textsuperscript{27,28}

**Measurement of thromboxane A2 generation**

Washed platelets at a concentration of \( 2 \times 10^8 \) platelets per milliliter were stimulated with 2-methylthio-adenosine-5’-diphosphate (2MeSADP) (5 nM, final) for 3.5 minutes. Levels of the stable analog thromboxane B2 were determined in duplicate using a Correlate-EIA thromboxane B2 enzyme immunoassay kit (Cayman Chemical) according to the manufacturer’s instructions.

**Western blotting**

Protein samples for platelets were prepared, and western blotting was performed, as previously described\textsuperscript{12,23,27,28}

**Confocal and transmission electron microscopy**

High-resolution, confocal reflection microscopy was performed using an Olympus IX81, FV300 (Melville, NY) confocal-scanning microscope equipped with a 60×/1.42 NA oil objective. For ultrastructural analyses, platelets were adhered to Acylar coated with poly-L-lysine and fixed in 2.5% glutaraldehyde in phosphate-buffered saline and processed as previously described.\textsuperscript{24}

**Statistical analyses**

Continuous variables from all experiments were assessed for normality with skewness and kurtosis tests. Data that were normally distributed were expressed as a mean plus or minus the standard error of the mean. For analyses involving 2 groups, a parametric 2-tailed Student t test was used. When 3 or more groups were analyzed, an analysis of variance with a Tukey post hoc test was performed. When data were not normally distributed, a Mann-Whitney was used when 2 groups were analyzed; a Kruskal-Wallis with a Dunn multiple comparison post hoc test was used for analyses of 3 or more groups. For correlations, we performed a Spearman correlation. Summary statistics were used to describe the study cohort and clinical variables were expressed as the mean plus or minus standard deviation or as a number and percentage. Statistical analyses were performed by using GraphPad Prism (version 7; San Diego, CA). A 2-tailed P value \(< .05\) was considered statistically significant.
COVID-19 patient cohort

COVID-19 patients were well matched by age, sex, and race to healthy donors (Table 1). SARS-CoV-2 virus was uniformly detected by PCR in patients diagnosed with SARS-CoV-2 infection. Approximately 41% of COVID-19 patients were in the ICU, of whom 53% required mechanical ventilation due to respiratory failure. Hospitalized non-ICU and ICU COVID-19 patients had comorbidities consistent with previously published studies, including hypertension, diabetes, and obesity.\(^3\),\(^2\). We observed a 17% mortality rate among all COVID-19 patients, consistent with hospitalized mortality rates (13.4%) in COVID-19 patients in Utah per the Utah Department of Health as of 8 June 2020.

The human platelet transcriptome is altered during SARS-CoV-2 infection

We and others have used transcriptomics to provide insights into how platelets are altered during acute inflammatory and infectious stressors, including viral pandemic pathogens.\(^1\),\(^2\),\(^3\),\(^4\) To determine whether the platelet transcriptome is altered in patients during SARS-CoV-2 infection, we performed RNA-seq on RNA isolated from highly purified platelets from 6 non-ICU and 4 ICU COVID-19 patients and 5 matched healthy donors recruited from the greater Salt Lake City area. As shown in Figure 1A, non-ICU and ICU COVID-19 patients clustered together, but separately from healthy controls in hierarchical clustering of transcriptome-wide gene expression, suggesting systemic alterations in platelet RNA expression. Differential gene-expression analysis revealed 3090 differentially expressed genes between non-ICU patients compared with healthy donors whereas 2256 were differentially expressed in ICU patients compared with healthy donors (false discovery rate < 0.05) (Figure 1B-D; supplemental Tables 1 and 2). Only 16 genes were differentially expressed in a direct comparison between non-ICU and ICU COVID-19 patients, suggesting minimal impact of ICU status (supplemental Table 3) on COVID-19–induced gene changes. Analysis of combined non-ICU and ICU patients (all COVID-19) compared with healthy donors identified 3325 differentially expressed genes (supplemental Figure 1; supplemental Table 4).

Ingenuity pathway analysis using differentially expressed genes in all COVID-19 vs healthy donors identified enriched pathways associated with protein ubiquitination, antigen presentation, and mitochondrial dysfunction in patients infected with COVID-19 (supplemental Table 5). To further assess the relevance of mitochondrial pathway–related gene changes, we measured mitochondrial reactive oxygen species (ROS) and basal phosphatidylserine (PS) expression in patient platelets because platelet PS exposure is a marker of mitochondrial-dependent platelet apoptosis. COVID-19 patients (both ICU and non-ICU) had increased basal ROS compared with healthy donors (supplemental Figure 2A-B). However, mitochondrial dysfunction did not result in increased platelet apoptosis, as PS expression was not different between COVID-19 patients and healthy donors (supplemental Figure 2C-D).

Table 1. Clinical characteristics of healthy donors and hospitalized patients with COVID-19

|                      | Healthy donors, n = 17 | COVID-19 patients | P     |
|----------------------|------------------------|-------------------|-------|
|                      | Non-ICU, N = 24        | ICU, N = 17       |       |
| Mean age (±SD), y    | 49.9 (±26.8)           | 48.1 (±15.9)      | .023  |
|                      | 62.5 (±14.4)           |                   |       |
| Male, %              | 53                     | 45.8              | .63   |
|                      |                        | 58.8              |       |
| Hispanic/Latino, %   | 12                     | 29.2              | .075  |
|                      |                        | 47.1              |       |
| Mean BMI (±SD)       | 33.6 (±9.0)            | 30.6 (±8.8)       | .31   |
|                      |                        |                   |       |
| Diabetes, %          | 0                      | 25.0              | <.001 |
|                      |                        | 64.7              |       |
| Hypertension, %      | 0                      | 33.3              | .279  |
|                      |                        | 47.1              |       |
| Mean SOFA (±SD)      | 1.8 (±1.1)             | 4.7 (±1.2)        | <.001 |
|                      |                        |                   |       |
| ARDS, %              | 8.3                    | 94.1              | <.001 |
|                      |                        |                   |       |
| MV, %                | 0                      | 53                | <.001 |
|                      |                        |                   |       |
| Survival to date, %  | 100                    | 64.7              | <.001 |
|                      |                        |                   |       |
| Aspirin, %           | 12.5                   | 11.8              | .95   |
|                      |                        |                   |       |
| Hydroxychloroquine, %| 16.7                   | 29.4              | .34   |
|                      |                        |                   |       |
| Remdesivir, %        | 20.8                   | 23.5              | .84   |
|                      |                        |                   |       |
| Convalescent plasma, %| 0                     | 5.9               | .24   |
|                      |                        |                   |       |
| Mean WBC (±SD)       | 6.1 (±2.3)             | 8.2 (±2.1)        | .005  |

BMI, body mass index; MV, mechanical ventilation; SD, standard deviation; SOFA, Sequential Organ Failure Assessment score; WBC, white blood count.

Results

COVID-19 patient cohort

COVID-19 patients were well matched by age, sex, and race to healthy donors (Table 1). SARS-CoV-2 virus was uniformly detected by PCR in patients diagnosed with SARS-CoV-2 infection. Approximately 41% of COVID-19 patients were in the ICU, of whom 53% required mechanical ventilation due to respiratory failure. Hospitalized non-ICU and ICU COVID-19 patients had comorbidities consistent with previously published studies, including hypertension, diabetes, and obesity.\(^3\),\(^2\). We observed an 17% mortality rate among all COVID-19 patients, consistent with hospitalized mortality rates (13.4%) in COVID-19 patients in Utah per the Utah Department of Health as of 8 June 2020.

The human platelet transcriptome is altered during SARS-CoV-2 infection

We and others have used transcriptomics to provide insights into how platelets are altered during acute inflammatory and infectious stressors, including viral pandemic pathogens.\(^1\),\(^2\),\(^3\),\(^4\) To determine whether the platelet transcriptome is altered in patients during SARS-CoV-2 infection, we performed RNA-seq on RNA isolated from highly purified platelets from 6 non-ICU and 4 ICU COVID-19 patients and 5 matched healthy donors recruited from the greater Salt Lake City area. As shown in Figure 1A, non-ICU and ICU COVID-19 patients clustered together, but separately from healthy controls in hierarchical clustering of transcriptome-wide gene expression, suggesting systemic alterations in platelet RNA expression. Differential gene-expression analysis revealed 3090 differentially expressed genes between non-ICU patients compared with healthy donors whereas 2256 were differentially expressed in ICU patients compared with healthy donors (false discovery rate < 0.05) (Figure 1B-D; supplemental Tables 1 and 2). Only 16 genes were differentially expressed in a direct comparison between non-ICU and ICU COVID-19 patients, suggesting minimal impact of ICU status (supplemental Table 3) on COVID-19–induced gene changes. Analysis of combined non-ICU and ICU patients (all COVID-19) compared with healthy donors identified 3325 differentially expressed genes (supplemental Figure 1; supplemental Table 4).

Ingenuity pathway analysis using differentially expressed genes in all COVID-19 vs healthy donors identified enriched pathways associated with protein ubiquitination, antigen presentation, and mitochondrial dysfunction in patients infected with COVID-19 (supplemental Table 5). To further assess the relevance of mitochondrial pathway–related gene changes, we measured mitochondrial reactive oxygen species (ROS) and basal phosphatidylserine (PS) expression in patient platelets because platelet PS exposure is a marker of mitochondrial-dependent platelet apoptosis. COVID-19 patients (both ICU and non-ICU) had increased basal ROS compared with healthy donors (supplemental Figure 2A-B). However, mitochondrial dysfunction did not result in increased platelet apoptosis, as PS expression was not different between COVID-19 patients and healthy donors (supplemental Figure 2C-D).
We next compared previously published,\textsuperscript{12,21} platelet RNA-seq data sets from septic patients and influenza A/H1N1 patients studied during the 2009 pandemic. Of note, numerous gene changes were unique for each disease condition (supplemental Figure 3; supplemental Tables 6-8). However, of the differentially expressed genes that were shared between COVID-19 and sepsis or H1N1, nearly all (\textasciitilde 96\%) changed in the same direction, suggesting convergent mechanisms driving these changes. Accordingly, enrichment analysis indicated distinct pathway changes in sepsis and H1N1 compared with COVID-19, but with some pathway changes shared including those related to antigen presentation and immune regulation (supplemental Tables 5, 9, and 10).

Regarding immune regulation, we previously identified that interferon-induced transmembrane protein 3 (IFITM3), an antiviral immune protein, was highly expressed in platelets during influenza A/H1N1 and dengue infection, but absent in platelets from healthy donors.\textsuperscript{12} In human megakaryocytes, IFITM3 functions to limit dengue viral infectivity. Interestingly, a variant in IFITM3 causing an N-terminally truncated protein that is associated with loss of function and increased viral replication in vitro, correlates clinically with severe COVID-19.\textsuperscript{20} RNA-seq analysis from both non-ICU and ICU COVID-19 patients revealed IFITM3 as 1 of the top significantly differentially expressed genes in platelets (Figure 2A; ICU patient shown). Western blot analysis confirmed that IFITM3 was significantly upregulated in both non-ICU and ICU patients (Figure 2B). Because IFITM3 regulates viral infectivity, we further examined our RNA-seq data set for the presence of angiotensin-converting enzyme 2 (ACE2), the putative receptor for SARS-CoV-2 binding, in platelets. RNA-seq demonstrated no expression of ACE2 mRNA independent of ICU status (supplemental Tables 1, 2, and 4). Furthermore, we did not detect ACE2 in platelets either by quantitative real-time PCR in 25 COVID-19 patients (ICU and non-ICU) and 5 healthy donors or by western blot (Figure 2C-D). We also did not detect ACE2 mRNA in megakaryocytes cultured from healthy human donors (not shown). Consistent with this, in the majority of patients with SARS-CoV-2 infection (n \textasciitilde 23 of 25; 92\%), the mRNA from the SARS-CoV-2 N1 gene was undetectable in isolated platelets. Interestingly, in isolated platelets from 2 ICU COVID-19 patients, for whom the ACE2 receptor was not expressed based on real-time PCR (n \textasciitilde 2 of 25; 8\%), we did detect mRNA expression of the SARS-CoV-2 N1 gene (Figure 2E and data not shown). Taken together, our data suggest that the platelet transcriptome is altered during SARS-CoV-2 infection. These data also demonstrate that human platelets do not express ACE2 mRNA or protein.
Platelet number, size, and morphology in COVID-19 patients

As COVID-19 alters the platelet transcriptome, we next sought to determine whether SARS-CoV-2 infection induced changes in platelet function consistent with the thrombotic phenotype observed in COVID-19 patients. 31-33 Viral and bacterial infections are commonly associated with thrombocytopenia and alterations in platelet morphology. Therefore, we tested whether patients with SARS-CoV-2 had changes in platelet count, mean platelet volume (MPV; a surrogate of platelet size and age), or their ultrastructure. Non-ICU and ICU COVID-19 patients generally had a platelet count and MPV in the normal reference range (Figure 3A-B). Although platelet counts and MPV were within normal ranges, plasma thrombopoietin (TPO) levels were significantly elevated in all COVID-19 patients (Figure 3C; supplemental Figure 4). TPO levels significantly correlated with platelet count in COVID-19 patients (supplemental Figure 4). Although TPO plasma levels were elevated in all COVID-19 patients, RNA-seq revealed that c-MPL, the gene encoding the TPO receptor, was significantly decreased (threefold in COVID-19 patients).

We next examined platelet morphology and ultrastructure during SARS-CoV-2 infection using a transmission electron microscope. We analyzed >50 platelets from 4 COVID-19 patients (3 ICU and 1 non-ICU) and, for comparison, 4 matched healthy
donors. Representative transmission electron microscope images are shown in Figure 3D. Platelets from both healthy donors and COVID-19 patients had similar appearances of the open canicular system, α and dense granules, mitochondria, and microtubular coils around the periphery of the platelet. In addition to examining morphology, we also examined platelets for the presence of SARS-CoV-2 virus as previous studies have demonstrated that platelets are capable of internalizing influenza virus.14 Consistent with our findings that the SARS-CoV-2 N1 gene was undetectable in the vast majority of isolated platelets (Figure 2E), we did not visually identify SARS-CoV-2 virus particles in these 4 platelet samples.

COVID-19 increases platelet surface P-selectin expression and circulating PLAs

Previous reports demonstrated that α-granule release and PLA formation are often increased during acute infections and may correlate with adverse clinical outcomes.34,35 We therefore next asked whether platelet P-selectin surface expression, a marker of platelet activation, was altered during COVID-19. Basal P-selectin surface expression was modestly, but significantly, increased in all COVID-19 patients independent of ICU status (Figure 4A; supplemental Figure 5B), compared with healthy donors. We also examined plasma levels another α-granule marker, platelet-derived growth factor (PDGF) AA/BB.36,37 Similar to basal levels of P-selectin expression, PDGF was significantly elevated in non-ICU and ICU patients compared with healthy donors (726.8 ± 106.8 ng/mL vs 2540.3 ± 347.9 ng/mL and 1988.3 ± 178.1 ng/mL; P < .05). Basal P-selectin expression correlated with soluble PDGF (r = 0.63; P = .076).

Activating platelets with low-dose 2MeSADP and PAR1 peptide (SFLLRN or TRAP) induced significantly greater surface P-selectin expression in all COVID-19 patients (Figure 4B; supplemental Figure 5C). Similar results were observed in all COVID-19 patient platelets treated with higher concentrations of 2MeSADP to trigger maximal platelet activation (supplemental Figure 5D-E). No differences between ICU and non-ICU COVID-19 patients were observed in regards to P-selectin expression. However, platelet P-selectin expression in response to low-dose 2MeSADP significantly correlated with illness severity based on SOFA scores (r = 0.5296; P = .037). As P-selectin is an important receptor for forming PLAs, we next examined PLAs during SARS-CoV-2 infection. Platelet-neutrophil, platelet-monocyte, and platelet-T cell (CD4+ and CD8+) aggregates were all significantly elevated in all COVID-19 compared with healthy donors (Figure 4C-F; supplemental Figure 6). Platelet-neutrophil aggregates (PNAs) were higher in ICU patients whereas platelet–T cell (CD4+) aggregates were generally higher in non-ICU COVID-19 patients. No differences were observed between
ICU and non-ICU COVID-19 patients with platelet-monocyte and platelet-T cell (CD8$^+$) aggregates (supplemental Figure 6).

Interestingly, platelet activation through 2MeSADP, SFLLRN (TRAP), and collagen-related peptide (CRP) resulted in decreased PAC-1 binding in all COVID-19 patients independent of ICU status compared with healthy donors (supplemental Figure 7). A similar decrease in PAC-1 binding was observed with high-dose agonists (supplemental Figure 7). The decrease in PAC-1 binding was not due to changes in αIIb expression as αIIb expression was similar among healthy donors and all COVID-19 patients (supplemental Figure 8).

Platelet aggregation is increased in COVID-19 patients

As procoagulant responses and clinical thrombosis are increased in patients with SARS-CoV-2 infection$^{29,38-40}$ and, because we observed evidence of increased platelet activation in all COVID-19 patients (Figure 4; supplemental Figures 5 and 6), we next assessed platelet aggregation. Platelet aggregation in response to low-dose agonists (2MeSADP, thrombin, and collagen) was significantly increased in COVID-19 patients compared with healthy donors (Figure 5A-B; supplemental Figure 9). The potentiation in aggregation was more pronounced in ICU patients, especially at lower doses of thrombin and 2MeSADP (supplemental Figure 9). At higher doses, this effect was less marked with 2MeSADP and collagen, inducing significantly greater platelet aggregation (Figure 5A-B) with similar increases observed in all COVID-19 patients (supplemental Figure 9). Platelets from non-ICU and ICU COVID-19 patients also exhibited greater adhesion and spreading on fibrinogen and collagen (Figure 5C-F). Taken together, these findings indicate that during clinical infection with SARS-CoV-2, platelets may circulate, primed to be hyperreactive.

Activation of MAPK-signaling pathway is upregulated in COVID-19 patient platelets

As platelet aggregation in COVID-19 patients was increased, especially in critically ill ICU patients, we next examined signaling events downstream of MAPK, a pathway mediating platelet aggregation. Phosphorylation of ERK1/2, p38, and eIF4E was significantly upregulated in platelets from critically ill ICU COVID-19 patients, indicating increased activation of the MAPK pathway (Figure 6A-B). Previous studies have shown that

**Figure 4. COVID-19 alters platelet activation and increases PLAs.** (A) Platelet P-selectin expression was measured in whole blood by flow cytometry at baseline in 17 healthy donors and 5 non-ICU and 12 ICU COVID-19 patients. Blue dots indicate ICU patients; red dots indicate non-ICU patients. (B) P-selectin expression was measured after activation by platelet agonists. P2Y12 activation was induced by 1 ng/mL 2MeSADP, PAR1 was activated through 2.5 μM SFLLRN (TRAP), and GPVI was activated with 1 ng/mL CRP (N = 17-18 per group). Blue dots indicate ICU patients; red dots indicate non-ICU patients. (C-F) PLAs were measured in whole blood by flow cytometry. N = 7 for the healthy donors and N = 12-13 for COVID-19 patients. Blue dots indicate ICU patients; red dots indicate non-ICU patients. (C) PNAs were identified as CD66b$^+$CD41$^+$ leukocytes. (D) Platelet-monocyte aggregates were identified as CD14$^+$CD41$^+$ leukocytes. (E) Platelet-CD4 T-cell aggregates were identified as CD3$^+$CD4$^+$CD41$^+$ leukocytes. (F) Platelet-CD8 T-cell aggregates were identified as CD3$^+$CD8$^+$CD41$^+$ leukocytes. *P < .05, ***P < .001.
increased MAPK signaling promotes thromboxane generation by regulating cytosolic phospholipase A2 activation. Therefore, we next evaluated platelet cytosolic phospholipase A2 phosphorylation in patients infected with SARS-CoV-2. As shown in Figure 6C-D, cytosolic phospholipase A2 phosphorylation was significantly increased in SARS-CoV-2–infected patients both at baseline and upon activation. Our laboratory and others have shown that increases in cytosolic phospholipase A2 phosphorylation activate cytosolic phospholipase A2 activity, thereby upregulating thromboxane production. Consistent with these
previous findings, stimulation with 2MeSADP resulted in increased thromboxane generation by platelets from COVID-19 ICU patients (Figure 6E). Platelet hyperreactivity in COVID-19 ICU patients could be reduced by pretreatment with high-dose aspirin (supplemental Figure 10). These results demonstrate that increased platelet activation (granule release and P-selectin expression) and aggregation during COVID-19 is due, at least in part, to increased MAPK pathway activation and thromboxane generation.

Discussion

COVID-19 is most commonly associated with ARDS and hypoxemic respiratory failure. Significant derangements in the coagulation cascade have been observed in critically ill COVID-19 patients, including elevated D-dimers, fibrinogen, and von Willebrand factor levels. Furthermore, thrombosis, including pulmonary embolism, venous thrombosis, and ischemic stroke, are common among severely ill patients. Platelets are known to play a significant role in the development of these thrombotic complications. In addition, platelets are an important bridge between the hemostatic system and immune defense, including viral illness. Whether COVID-19 alters platelet gene expression and function is unknown. Here, we demonstrate for the first time that COVID-19 significantly alters platelet gene expression and triggers robust platelet hyperreactivity.

Previous studies from our group have demonstrated that infectious diseases including dengue, influenza, and sepsis are associated with dynamic changes in platelet gene expression. Similar to other infectious diseases, the platelet transcriptome was significantly altered in COVID-19 patients, as compared with healthy donors. Interestingly, non-ICU and ICU COVID-19 patients
had similar changes in gene expression with only 16 genes differentially expressed between the 2 cohorts.

Although global transcriptomic changes were similar between both non-ICU and ICU COVID-19 patients, hundreds of platelet transcripts significantly differentially expressed during COVID-19 were distinctly different than those transcripts altered during pandemic influenza A/H1N1 or sepsis. This suggests there may be unique aspects of COVID-19 on platelets that are distinct from those changes triggered during sepsis and pandemic influenza A/H1N1. We highlight that there were also a number of transcripts that were similarly altered in platelets from patients with COVID-19 and pandemic influenza A/H1N1. This included the interferon-sensitive gene IFITM3, which prevents viral entry and replication. Interestingly, IFITM3 expression was similar among ICU and non-ICU COVID-19 patients. We recently reported that IFITM3 mRNA and protein are upregulated in platelets and megakaryocytes during viral infections, and functionally serve to limit viral infection of host cells, including megakaryocytes and stem cells. Whether upregulation of IFITM3 in platelets from COVID-19 patients serves to similarly restrict SARS-CoV-2 viral replication remains unknown at this time, but may be pursued in future studies.

Recent studies have suggested that viruses such as influenza can be found in platelets. Whether SARS-CoV-2 virus can bind to and enter platelets has not previously been established. Using complementary transcriptomic and proteomic assays, we were uniformly unable to detect ACE2, the putative receptor for SARS-CoV-2 viral entry, in platelets or megakaryocytes. Transmission electron microscopy also revealed the absence of SARS-CoV-2 viral particles in platelets. We did detect, in a very small number of COVID-19 patients (n = 2 of 25; 8% both COVID-19 ICU patients), transcriptional expression of the N1 SARS-CoV-2 gene in isolated platelets. Both patients had no detectable expression of the ACE2 receptor based on real-time PCR analysis. We were unable to determine whether SARS-CoV-2 virion particles were also present in platelets from these 2 COVID-19 patients as we did not perform electron microscopy on these patients. Because our findings indicate that the ACE2 receptor is absent in platelets and megakaryocytes, if SARS-CoV-2 viral uptake occurs, it would seemingly need to happen independently of the ACE2 receptor. As platelets express a host of TLRs, including TLR7, it is possible that SARS-CoV-2 could enter megakaryocytes and platelets through an alternative mechanism.

Although thrombocytopenia is observed in some COVID-19 patients and correlates with mortality, patients we recruited with COVID-19 (ICU and non-ICU) generally had normal platelet number and size, consistent with at least 1 prior report. This is distinct from other viral infectious diseases including more severely ill influenza patients, as well as dengue and SARS-CoV-1.

Interestingly, over one-half of SARS-CoV-1 patients present with thrombocytopenia with no change in TPO levels until the convalescence stage of the disease when TPO levels increase as well as platelet counts. Viral infections are known to modulate liver production of TPO due to alterations in host cytokine profiles such as increased tumor growth factor β. In our study, increased TPO levels in COVID-19 patients without alterations in platelet counts may reflect the systemic effects present in patients during infection altering liver production of TPO. Alternatively, we observed significantly decreased c-MPL RNA levels in COVID-19 patients. Decreased TPO receptor on platelets and megakaryocytes has been shown to affect circulating TPO levels and may also explain our observation in COVID-19 patients.

Platelet activation is common during infectious diseases, including PS exposure. Although we validated enrichment of 1 ingenuity pathway analysis pathway (mitochondrial dysfunction) with functional changes demonstrating increased mitochondrial ROS generation in COVID-19 patients, we did not observe any increase in resting PS levels. These findings illustrate 1 difference in platelets during SARS-CoV-2 infection and other infectious setting, including HIV infection and sepsis. Platelets also contain many antiviral and antibacterial factors inside their α- and dense granules, which are secreted by activated platelets. Previous studies have observed increased P-selectin expression during viral infection including influenza. Increased expression of P-selectin promotes the formation of PLAs through P-selectin glycoprotein ligand-1 (PSGL-1). The formation of PLAs is a very sensitive marker of in vivo platelet activation during infectious disease, and we observed increased PLAs in COVID-19 patients. PLA formation, specifically with monocytes, also induces fibrin clot formation via interactions of PSGL-1 on leukocyte-derived microparticles with tissue factor on the platelet surface. Similar to other critically ill patient populations, circulating platelet-monocyte aggregates in blood were significantly increased independent of ICU status in COVID-19 patients. We also identified that circulating PNAs were increased in COVID-19 patients and were higher in ICU patients. The formation of PNAs recruits neutrophils to damaged lung capillaries. Selectin neutralization reduces neutrophil recruitment and inhibits the development of acute lung injury in animal models. P-selectin blockade is being investigated during SARS-CoV-2 infection and we speculate that increased PNAs may contribute to the acute lung damage and ARDS observed in COVID-19.

Although not as often studied during infectious diseases, increased platelet T-cell interactions may also influence outcomes during SARS-CoV-2 infections. Previous studies have demonstrated increased neuroinflammation, commonly reported in COVID-19, and altered IL-17 and IFNγ production when platelets adhere to CD4+ T cells. In addition to regulating T-cell inflammatory responses, platelets express major histocompatibility class I (MHC-I) and are capable of cross-presenting antigens to CD8+ T cells. Viral infections such as dengue are known to effect platelet MHC expression and proteasome activity. Increased platelet T-cell interactions may modulate T-cell reactivity, inflammation, and immune responses during COVID-19 and warrant further investigation.

We observed increased platelet aggregation in response to 2MesADP, thrombin, and collagen as well as increased adhesion and spreading of platelets on fibrinogen and collagen during infection with SARS-CoV-2. Critically ill ICU COVID-19 patients had increased aggregation in response to low-dose agonist compared with non-ICU patients, suggesting more severe disease may induce greater platelet hyperreactivity. Increased platelet aggregation has been observed in other viral illness such as HIV, where subthreshold concentrations of agonists induce greater platelet aggregation similar to our observations during SARS-CoV-2 activation. Increased MAPK signaling may be partly responsible for the increased aggregation responses as we observed increased activation of cytosolic phospholipase A2 and subsequently increased
Aspirin pretreatment of platelets from SARS-CoV-2–infected patients abolishes this hyperactivity (supplemental Figure 10), further supporting increased thromboxane generation as 1 mechanism triggering platelet hyperreactivity during COVID-19. Of note, platelet aggregation was assessed only on COVID-19 patients who were not on aspirin or other antiplatelet agents. Interestingly, platelet P-selectin expression in response to low-dose 2MeSADP significantly correlated with illness severity based on SOFA scores. A recent report indicated that ADP is a key player in the development of microvascular thrombosis in COVID-19 patients.21 As aspirin reduced platelet hyperactivity in COVID-19 patients, our findings of platelet activation correlating with illness severity further suggest that antiplatelet therapies may be warranted in treating COVID-19 patients. Enhanced MAPK signaling could also be responsible for increased α-granule release and P-selectin expression observed in COVID-19 patients.22

Increased activation of the MAPK pathway in platelets may be partly due to increased JAK3, which is known to be upstream of the MAPK pathway.23 RNA-seq analysis demonstrated increased JAK3 mRNA expression, which we subsequently validated at the protein level (supplemental Figure 11). In addition to JAK3, we also observed that other upstream regulators of the MAPK pathway were altered in platelets during COVID-19, including signaling by Rho family GTPases (supplemental Table 5).

However, not all aspects of platelet functional responses were enhanced in COVID-19. Integrin αIIbβ3 activation was reduced during COVID-19, compared with healthy donors. A similar finding was previously observed in critically ill influenza A/H1N1 (which caused the 2009 pandemic) patients, suggesting that reduced integrin activation may be a common feature of acute viral illness.24 The mechanism behind reduced integrin αIIbβ3 activation (and its significance) remains unknown. Our flow cytometry analyses indicated that αIIb expression was similar between COVID-19 patients and controls, however, suggesting that reduced αIIb receptor density was not responsible for this finding. We did observe that calpain mRNA expression was significantly upregulated in platelets during SARS-CoV-2 infection (supplemental Tables 2 and 4). As mitochondrial-dependent calpain activation regulates integrin αIIbβ3,25 it is possible that altered mitochondria function and increased calpain levels may contribute to our observation of reduced integrin αIIbβ3 activation in COVID-19 patients.

Based on the results of our study, we postulate that increased platelet reactivity during SARS-CoV-2 infection may contribute to immunothrombosis during COVID-19 as reported by others.31,43 As none of the COVID-19 patients enrolled in our study were clinically diagnosed with thrombotic complications, we are unable to examine clinical associations between platelet activation and thrombosis in our study. Interestingly, platelet counts, MPV, and markers of platelet activation, including platelet-leukocyte and plasma PDGF, did not correlate with markers of inflammation such as IL-6, IL-8, and TNF-α (data not shown). We also posit that platelets are likely not the sole contributors, as other blood cells and soluble coagulation factors also mediate injurious inflammatory, immune, and thrombotic responses.

In conclusion, our findings demonstrate that COVID-19 is associated with substantial alterations in the platelet transcriptome and proteome, and platelet hyperreactivity. Our data may serve as foundational to ongoing clinical studies investigating whether targeting platelets during COVID-19 may improve patient outcome.

**Acknowledgments**

The authors acknowledge the figure preparation expertise of Diana Lim and assistance with participant recruitment from Antoinette Blair, Macy Barnos, Amber Plante, Jordan Greer, Amy DeNardo, Amanda Bailey, and Lindsey Waddoups. The authors also acknowledge Nancy Chandler, Willisa Liou, and the University of Utah Electron Microscopy Core Laboratory for their assistance with the electron microscopy.

This work was supported by the following National Institutes of Health grants: Eunice Kennedy Shriver National Institute of Child Health and Human Development grant R01099326 (C.C.Y.); National Heart, Lung, and Blood Institute grant R10HL135265 (A.C.P.); National Institute on Aging grant K01AG059892 (R.A.C.); National Heart, Lung, and Blood Institute grants R35HL145237 (A.S.W.) and R01HL142804 (M.T.R. and A.S.W.); National Institute on Aging grants R01AG048022 and R56AG059877; and National Heart, Lung, and Blood Institute grant R01HL130541 (M.T.R.). This work was also supported by grants from the University of Utah Triple I Program (E.A.M.), Fonds voor Wetenschappelijk Onderzoek Vlaanderen PWO 12U7818N (F.D.), and the American Heart Foundation (18Post340300200 [B.K.M.]). This work was also supported in part by Merit Review award number 101 CX001696 (M.T.R.) from the US Department of Veterans Affairs Clinical Sciences R&D (CSRD). This material is the result of work supported with resources and the use of facilities at the George E. Wahlen VA Medical Center (Salt Lake City, UT). Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1510RR026802-01. Research reported in this publication used the High-Throughput Genomics and Bioinformatic Analysis Shared Resource at Huntsman Cancer Institute at the University of Utah and was supported by the National Cancer Institute of the National Institutes of Health under award number F30CA042014. The work was also supported by the Flow Cytometry Core at the University of Utah.

**Authorship**

Contribution: B.K.M., F.D., E.A.M., I.P., J.W.R., L.G., A.C.P., N.D.T., M.C., C.C.Y., M.T.R., and R.A.C. designed and performed experiments; B.K.M., F.D., E.A.M., I.P., J.W.R., C.S., N.D.T., M.T.R., and R.A.C. analyzed results and made the figures; B.K.M., F.D., E.A.M., I.P., J.W.R., A.S.W., M.T.R., and R.A.C. wrote the paper; and all authors reviewed and critically edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: B.K.M., 0000-0001-6848-4484; F.D., 0000-0003-1442-3568; R.A.C., 0000-0003-0027-694X.

Correspondence: Robert A. Campbell, Eccles Institute of Human Genetics, University of Utah Health Sciences Center, 15 North 2030 East, Bldg 333, Suite 4225, Salt Lake City, UT 84112; e-mail: rcampbell@u2m2.utah.edu.

**Footnotes**

Submitted 22 May 2020; accepted 18 June 2020; prepublished online on Blood First Edition 23 June 2020. DOI 10.1182/blood.2020007214.

*B.K.M., F.D., and E.A.M. contributed equally.

The RNA-seq data reported in this article are available at BioProject (accession #PRJNA634489).

The online version of this article contains a data supplement.

There is a Blood Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
REFERENCES

1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.

2. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series [published online ahead of print 14 May 2020]. Am Intern Med. doi:10.7322/M20-2566.

3. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-342.

4. Poissy J, Goutay J, Caplan M, et al; Lille ICU Center, clinicopathologic case series [published online ahead of print 14 May 2020]. Ann Intern Med. doi:10.7322/M20-2566.

5. Guo L, Rondina MT. The era of thrombomodulation: platelets are dynamic sensors and effector cells during infectious diseases. Front Immunol. 2019;10:2204.

6. Middleton EA, Weyrich AS, Zimmerman GA. Platelets in pulmonary immune responses and inflammatory lung diseases. Physiol Rev. 2016;96(4):1211-1259.

7. Kouprenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018;122(2):337-351.

8. Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264-274.

9. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194(12):5579-5587.

10. Zufferey A, Speck ER, Machlus KR, et al. Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets. Blood Adv. 2017;1(20):1773-1785.

11. Boilard E, Paré G, Rousseau M, et al. Engagement of the platelet-derived chemokine CXCL4/FLM as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci USA. 2012;109(24):9569-9574.

12. Kraemer BF, Campbell RA, Schwartz H, et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog. 2011;7(11):e1002355.

13. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun. 2002;70(12):6524-6533.

14. Engelmann B, Masberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.

15. Middleton EA, Rowley JW, Campbell RA, et al. Sepsis alters the transcriptional and translational landscape of human and murine platelets. Blood. 2019;134(12):911-923.

16. Rondina MT, Yoon D, Simon LM, et al. Longitudinal RNA-Seq analysis of the repeatability of gene expression and splicing in human platelets identifies a platelet SELP splice QTL. Circ Res. 2020;126(4):501-516.

17. Campbell RA, Franks Z, Bhatnagar A, et al. Granzyme A in human platelets regulates the synthesis of proinflammatory cytokines by monocytes in aging. J Immunol. 2018;200(1):295-304.

18. Campbell RA, Vieira-de-Abreu A, Rowley JW, et al. Clots are potent triggers of inflammatory cell gene expression: indications for timely fibrinolysis. Arterioscler Thromb Vasc Biol. 2017;37(10):1819-1827.

19. Rondina MT, Schwartz H, Harris ES, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost. 2011;9(4):748-758.

20. Rondina MT, Brewster B, Grissom CK, et al. In vivo platelet activation in critically ill patients with primary 2019 influenza A/H1N1. Chest. 2012;141(6):1490-1495.

21. Manne BK, Bhatlekar S, Middleton EA, Weyrich AS, Borst O, Rondina MT. Phosphoinositol-dependent kinase 1 regulates signal-dependent translation in megakaryocytes and platelets. J Thromb Haemost. 2020;18(5):1183-1196.

22. Manne BK, Münzer P, Badolia R, et al. PDK1 enhances dengue virus-induced lethality via vesicles from CLEC2-activated platelets enriching dengue virus-induced lethality via CLEC2A/TLR2. Nat Commun. 2019;10(1):1.

23. Zhang Y, Qin L, Zhao Y, et al. Interferon-α/β restricts the morbidity and mortality associated with in vitro platelet activation in acute stroke with and without preceding infection. Anticancer Res. 2019;39(4):1179-1185.

24. Beyrouti R, Adams ME, Benjamin L, et al. Engagement of the platelet-derived chemokine CXCL4/FLM as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci USA. 2012;109(24):9569-9574.

25. Kadereit J, Tacquard C, Severac F, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

26. Kaplan DR, Chao FC, Stiles CD, Antoniades GN, Scher CD. Platelet alpha-granules contain a growth factor for fibroblasts. Blood. 1979;53(6):1043-1052.

27. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlations. Blood Rev. 2009;23(4):177-189.

28. Helms J, Tacquard C, Severac F, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

29. Liltjos JF, Ledicr M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients [published online ahead of print 22 April 2020]. J Thromb Haemost. doi:10.1111/jh.14869.

30. Fan BE, Chong VCL, Chan SWM, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6):E131-E134.

31. Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020;91(8):889-891.

32. Klok FA, Kruijp MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

33. Lodigiani C, Iapichino G, Carenzo L, et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.

34. Everitt AR, Clare S, Pertel T, et al; GenISIS Investigators; MOSAIC Investigators. IFITM3 organization and signaling. J Cell Biol. 2012;198(4):561-574.

35. Panigrahi S, Ma Y, Hong L, et al. Engagement of platelet toll-like receptor 9 by novel...
platelet endogenous ligands promotes platelet hyperreactivity and thrombosis. **Circ Res.** 2013;112(1):103-112.

47. Koupova M, Viteva O, MacKay CR, et al. Platelet-TRLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. **Blood.** 2014;124(5):791-802.

48. Banerjee M, Huang Y, Joshi S, et al. Platelets endocytose viral particles and are activated via TLR (Toll-like receptor) signaling. **Arterioscler Thromb Vasc Biol.** 2020;40(7):1635-1650.

49. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. **Platelets.** 2020;31(4):490-496.

50. Hapsari Putri I, Tunjungputri RN, De Groot PG, van der Ven AJ, de Mast Q. Thrombocytopenia and platelet dysfunction in acute tropical infectious diseases. **Semin Thromb Hemost.** 2018;44(7):683-690.

51. Lopez-Delgado JC, Rovira A, Esteve F, et al. Thrombocytopenia as a mortality risk factor in acute respiratory failure in H1N1 influenza. **Swiss Med Wkly.** 2013;143:w13788.

52. Ojha A, Nandi D, Batra H, et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. **Sci Rep.** 2017;7:41697.

53. Yang M, Ng MH, Li CK, et al. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. **Thromb Res.** 2008;122(4):473-477.

54. Assinger A. Platelets and infection - an emerging role of platelets in viral infection. **Front Immunol.** 2014;5:649.

55. Metcalf Pate KA, Lyons CE, Dorsey JL, et al. TGFβ-mediated downregulation of thrombo-poietin is associated with platelet decline in asymptomatic SIV infection. **J Acquir Immune Defic Syndr.** 2014;65(5):510-516.

56. Lj J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. **Br J Haematol.** 2000;113(3):943-953.

57. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythaemia. **Blood.** 1997;90(10):4031-4038.

58. Fielder PJ, Gunney AL, Stefanich E, et al. Regulation of thrombopoietin receptor levels by c-mpl-mediated binding to platelets. **Blood.** 1996;87(6):2154-2161.

59. Mesquita EC, Hottz ED, Amancio RT, et al. Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. **Sci Rep.** 2018;8(1):14999.

60. Ma R, Xie R, Yu C, et al. Phosphatidylserine-exposed platelets participate in the intravascular hemolysis of ADP-fibrinogen-platelet macroaggregates. **Biomed Pharmacother.** 2018;109:24-35.

61. Lè VB, Schneider JG, Boergering Y, et al. Platelet activation and aggregation promote intravascular hemolysis. **J Exp Med.** 2003;197(11):1585-1598.

62. Caudrillier A, Kessenbrock K, Gilliss BM, et al. CCR3-Mediated binding to platelets. **J Clin Invest.** 2006;116(12):3211-3219.

63. Starrossom SC, Veremeyko T, Yung AW, et al. Platelets play differential role during the initiation and progression of autoimmune neuroinflammation. **Circ Res.** 2015;117(9):779-792.

64. Zamora C, Cantó E, Nieto JC, et al. Functional consequences of platelet binding to T lymphocytes in inflammation. **J Leukoc Biol.** 2013;94(3):521-529.

65. Chapman LM, Aggrey AA, Field DJ, et al. Platelets present antigen in the context of MHC class I. **J Immunol.** 2012;189(2):916-923.

66. Trugilo MR, Hotta ED, Brunoro GV, et al. Platelet protromte reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue. **PLoS Pathog.** 2017;13(5):e1006385.

67. Satchell CS, Cotter AG, O’Connor EF, et al. Platelet function and HIV: a case-control study. **AIDS.** 2010;24(5):649-657.

68. Bzowska T, Vats R, Bennewitz MF, et al. Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in pre-capillary pulmonary arteries. **JCI Insight.** 2020;5(39):e139437.

69. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractive signaling pathway. **Blood.** 2009;113(4):893-901.

70. Tibbles HE, Vassilev A, Wendorf H, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. **J Biol Chem.** 2001;276(21):17815-17822.

71. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyro- phostin AG-490 regulation of IL-2-mediated T cell response. **J Immunol.** 1999;162(7):3897-3904.

72. Mattheij NJ, Gilio K, van Kruchten R, et al. Dual mechanism of integrin αIβ3 closure in procoagulant platelets. **J Biol Chem.** 2013;288(19):13325-13336.